✦ LIBER ✦

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

✍ Scribed by Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vinci; Vera Clò; Barbara Casolari

Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 232 KB
Volume: 37
Category: Article
ISSN: 1040-8428
DOI: 10.1016/s1040-8428(00)00069-x

No coin nor oath required. For personal study only.

✦ Synopsis

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have demonstrated a strong activity of rituximab alone in indolent B non-Hodgkin lymphoma, especially in patients with follicular lymphoma. The most utilized dose-schedule is 375 mg/m(2) weekly x 4. The association with chemotherapy or with interferon-alpha increases Rituximab efficacy. More recently, Rituximab have showed activity also in diffuse large cell lymphoma, mantle cell lymphoma and in other B-malignancies. Good results have also been obtained utilizing Rituximab for in vivo purging. However, we are still far from having found a definite position for Rituximab in the treatment of lymphoproliferative disorders. The aim of future studies should be to develop new strategies that will hopefully produce the most effective Rituximab-based regimens in order to find the Rituximab key position in the treatment of B-malignancies

📜 SIMILAR VOLUMES

Experimental treatment of human diffuse

Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab

✍ Franck Assayag; Nicole Brousse; Jérôme Couturier; Elizabeth Macintyre; Claire Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 2 views

Synergistic cytotoxicity of iodine-131-a

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

✍ Timothy A. Johnson; Oliver W. Press 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 231 KB

Preliminary clinical trials suggest that iodine-131 ( 131 I)labeled anti-CD20 monoclonal antibodies (MAbs) are effective single agents for the treatment of relapsed non-Hodgkin's B-cell lymphomas. However, despite high initial response rates, most patients treated in this manner will eventually rela

Treatment of immune thrombocytopenia ass

Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab

✍ Ilene C. Weitz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 2 views

Reactivation of hepatitis B virus after

Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma

✍ Kosei Matsue; Shun-Ichi Kimura; Yoko Takanashi; Kan-Ichi Iwama; Hideaki Fujiwara 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Reduction of tumor burden and stabilizat

Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma

✍ Lucie M. Heinzerling; Margarete Urbanek; Jens O. Funk; Stefan Peker; Oliver Blec 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 687 KB

The advantage of residualizing radiolabe

The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody

✍ M. Jules Mattes; Lisa B. Shih; Serengulam V. Govindan; Robert M. Sharkey; Gaik L 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 104 KB

CD22 antibodies (Abs) bound to B-cell lymphomas are known to be internalized and catabolized rapidly. Therefore, it would be expected that use of CD22 as a target for radioimmunotherapy should be enhanced by the use of "residualizing" radiolabels, which are trapped within the cell after catabolism o